MHLW Revises Conditions of Approval for Alecensa Based on Findings from Post-Marketing Survey

The Ministry of Health, Labor and Welfare (MHLW) has revised conditions of approval for Chugai Pharmaceutical’s non-small cell lung cancer (NSCLC) treatment Alecensa (alectinib) based on the analysis of post-marketing survey results and future plan to ensure proper use. In...read more